Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: Implications in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 18, Issue 4, 2009, Pages 843-848

  Goi Oliver, Paloma ^a   Avila, Jesús ^a   Hernández, Félix ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer's disease; Calpain; Glycogen synthase kinase 3 (GSK 3); N methyl D aspartic acid (NMDA); Proteolysis

Indexed keywords

CALPAIN; CALPEPTIN; GLYCINE; GLYCOGEN SYNTHASE KINASE 3; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NEUROPROTECTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

EID: 74949097238     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1190     Document Type: Article

References (22)

1. Avila J, Hernandez F (2007) GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7, 1527-1533.
2. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29, 95-102.
3. Eldar-Finkelman H (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8, 126-132.
4. LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3, 862-872.
5. Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 90, 2628-2632.
6. Taniguchi S, Fujita Y, Hayashi S, Kakita A, Takahashi H, Murayama S, Saido TC, Hisanaga S, Iwatsubo T, Hasegawa M (2001) Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 489, 46-50.
7. Liu F, Grundke-Iqbal I, Iqbal K, OdaY, Tomizawa K,GongCX (2005) Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 280, 37755-37762.
8. Liang Z, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2007) Down-regulation of cAMP-dependent protein kinase by overactivated calpain in Alzheimer disease brain. J Neurochem 103, 2462-2470.
9. Camins A, Verdaguer E, Folch J, Pallas M (2006) Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12, 135-148.
10. Huang Y, Wang KK (2001) The calpain family and human disease. Trends Mol Med 7, 355-362.
11. Patrick GN, Zukerberg L, Nikolic M, Dela Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
12. Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83, 731-801.
13. Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2007) Nterminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 282, 22406-22413.
14. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
15. Hernandez F, Perez M, Lucas JJ, Mata AM, Bhat R, Avila J (2004) Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem 279, 3801-3806.
16. Goni-Oliver P, Avila J, Hernandez F (2009) Calpain-mediated truncation of GSK-3 in post-mortem brain samples. J Neurosci Res 87, 1156-1161.
17. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
18. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275, 17166-17172.
19. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364.
20. Czogalla A, Sikorski AF (2005) Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells. Cell Mol Life Sci 62, 1913-1924.
21. Sorimachi Y, Harada K, Yoshida K (1996) Involvement of calpain in postmortem proteolysis in the rat brain. Forensic Sci Int 81, 165-174.
22. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA (1997) Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res 763, 145-158.